

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/24766 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 7/00,**  
7/32, 7/34, 7/38

(21) International Application Number: **PCT/EP00/09144**

(22) International Filing Date:  
18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/157,382 1 October 1999 (01.10.1999) US

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): **UNILEVER PLC** [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).

(71) Applicant (for all designated States except AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, IN, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW): **UNILEVER NV** [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for IN only): **HINDUSTAN LEVER LIMITED** [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Maharashtra, 400 020 Mumbai (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MA, Zhuning**

[/US]; Unilever Home & Personal Care USA, 3100 East Golf Road, Rolling Meadows, Chicago, IL 60008 (US). **BRUCKS, Richard, Mark** [/US]; Unilever Home & Personal Care USA, 3100 East Golf Road, Rolling Meadows, Chicago, IL 60008 (US).

(74) Agents: **PEARCE, Timothy et al.**; Unilever PLC, Patent Department, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ANTIPERSPIRANT COMPOSITIONS COMPRISING MICROEMULSIONS**

(57) Abstract: Stable, clear, antiperspirant microemulsions containing cosmetic oils, antiperspirant salts, and water and combinations of cationic quaternary ammonium salt are provided. These microemulsions can be used in different types of applicators such as roll-on, sponge, mousse, pad, brush, gel and aerosol or non-aerosol spray applicators.

WO 01/24766 A1

- 1 -

**ANTIPERSPIRANT COMPOSITIONS COMPRISING MICROEMULSIONS****5 Field of the Invention**

This invention is related to microemulsions that contain cosmetically active ingredients. In a preferred embodiment, this invention is related to antiperspirant  
10 salt-containing microemulsions that are stable, clear liquids and are easy and inexpensive to produce.

**Background of the Invention**

15

The microemulsions of the present invention contain water. Microemulsions of the present invention are transparent or translucent, optically isotropic and thermodynamically stable mixtures of oil and water  
20 stabilized by surfactants and perhaps co-surfactants. The particle size of the dispersed phase of a microemulsion is about 100 to about 2000 angstroms, more preferably are about 100 to about 1000 angstroms. They can form spontaneously or with a little energy. Therefore they are simple to prepare  
25 and are not process dependent i.e. the order of addition of starting materials or speed / type of mixing is not critical to the preparation of the microemulsions. It would be desirable to formulate antiperspirant compositions using microemulsions because microemulsions are easy and  
30 inexpensive to process and can be inherently clear without

- 2 -

requiring refractive index matching of the aqueous and non-aqueous phases.

Microemulsions have attracted considerable  
5 technological and scientific interest. Water-in-oil (w/o)  
microemulsions containing water, an ionic surfactant, a  
cosurfactant and oil are the most investigated. The ionic  
surfactant- containing microemulsions usually exhibit  
stability over a large range of temperature. . When  
10 inorganic salts are added, the minimum surfactant level to  
form water-in-oil microemulsions will increase. As the  
hydrocarbon oil chain length increases, the solubilization  
of aqueous phase into the oil phase decreases, while the  
liquid crystal area increases. Nonionic surfactant-  
15 containing water-in-oil microemulsions require a large  
amount of surfactant as well. Unfortunately, nonionic  
surfactant-containing microemulsions commonly exhibit a  
small temperature range of stability

20 Microemulsions exist in the following forms: as water-  
in-oil, oil-in-water or as a *bicontinuous phase*, which is  
also called the *surfactant phase*. As used herein, the term  
"microemulsion means water-in-oil, oil-in-water or a  
bicontinuous phase, or mixtures thereof. Bicontinuous phase  
25 microemulsions are found to solubilize a high amount of  
water and oil with lower levels of surfactant. The region  
around a bicontinuous phase microemulsion may transition  
into a swollen lamellar phase, otherwise known as a liquid  
crystal phase, and in certain cases these phases  
30 (microemulsion and liquid crystal) may co-exist. These  
phases exhibit birefringence, shear induced (streaming)

- 3 -

birefringence, and are thixotropic, viscoelastic and transparent. Because some of these systems exhibit increased viscosity the technical literature may refer to them as microemulsion gels.

5

It is an object of the present invention to provide antiperspirant compositions, which contain high levels of antiperspirant salts, cosmetic oils and surfactants suitable for application to the axilla. It is also an object of the present invention to provide antiperspirant compositions that do not require refractive index matching of the aqueous and nonaqueous phases in order to be clear. It is also an object of the present invention to provide microemulsion antiperspirant compositions that require little energy to manufacture. These and other objects of the present invention will become more readily apparent in the present application.

Patents and patent documents, which are cited in connection with the disclosed invention, are as follows:

DE 196 42 090 A1 discloses cosmetic or dermatologic compositions based on microemulsions.

U.S. Patent 5,162,378 discloses water in oil microemulsions comprising cetyl dimethicone copolyol, water, silicone, alcohol, and 5-40% by weight of one or more salts.

U.S. Patent 5,705,562 discloses a method of spontaneously forming a highly stable clear microemulsion by combining water, a volatile cyclic methyl siloxane or a

- 4 -

volatile linear methyl siloxane and a silicone polyether surfactant. U.S Patent 5,707,613 is in the same patent family as the just mentioned patent.

5 WO 94/22420 is concerned with silicone-based skin care products, which are applied to the skin as aerosols and form a clear gel on the skin.

10 WO 94/19000 discloses pharmaceutical compositions in the form of a microemulsion which comprise an oil, a mixture of high and low HLB surfactants in which the high HLB surfactant comprises an aliphatic, aryl or aliphatic-aryl sulfate or sulfosuccinate or salt thereof, an aqueous phase and a biologically active agent.

15 WO 94/08610 discloses pharmaceutical compositions in the form of microemulsions which comprise an oil, a mixture of high and low HLB surfactants in which the high HLB surfactant comprises a medium-chain fatty acid salt, an aqueous phase and a biologically active agent.

20

U.S. 5,575,990 discloses roll-on antiperspirant compositions which are clear and, when applied to the human skin, do not leave a visible white residue after drying.

25 The clear antiperspirant roll-on compositions are stable under varying temperature conditions and provide a suitable cosmetically acceptable feel or sensation when applied to the human skin.

30 U.S. 5,487,887 discloses roll-on antiperspirant compositions and more particularly concerns antiperspirant

- 5 -

compositions which are clear and stable under varying temperature conditions and, when applied to the human skin, do not leave a visible white residue after drying. The compositions in the form of an oil-in-water microemulsion, 5 comprise an antiperspirant active 5-30, PEG-7-glyceryl cocoate 5-25, emollients 0.5-3, cyclomethicone 3-7, and water 53-60%.

## 10 Summary of the Invention

The invention relates to a composition in the form of a microemulsion comprising an antiperspirant salt, a cosmetic oil, and a combination of at least one cationic quaternary 15 surfactant and at least one nonionic surfactant.

## Detailed Description of the Invention

20 The present invention is directed to antiperspirant salt-containing microemulsions that are stable and clear liquids, or clear antiperspirant gels.

Stable clear microemulsions containing cosmetic oils, 25 antiperspirant salt, water, quaternary surfactants and nonionic surfactants have been discovered. The microemulsions are primarily composed of bicontinuous phase but the compositions include water-in-oil, oil-in-water, and microemulsion gels (liquid crystals). The microemulsions 30 are novel antiperspirant compositions that can be used in different types of applicators such as roll-on, sponge,

- 6 -

mousse, pad, wipe, brush, gel and aerosol or non-aerosol spray applicators.

The microemulsions discovered in this invention contain  
5 inorganic salts such as antiperspirant salts and cosmetic oils and the solubilization of high levels of both oil and aqueous solution of salts is achieved by incorporating combinations of a quaternary ammonium surfactant and a nonionic surfactant.

10

More specifically, the invention relates to a composition in the form of a microemulsion comprising an antiperspirant salt, cosmetic oils, and a combination of at least one cationic quaternary surfactant and at least one  
15 nonionic surfactant.

The invention also relates to a method for controlling or preventing underarm perspiration and malodor, which comprises applying to the underarm area a composition  
20 according to the invention.

The characteristics of the microemulsions of this invention include one or more of:

- 25
- The microemulsions exhibit stability over a relatively large range of temperature.
  - The viscosity ranges from a thick gel to a low viscosity sprayable liquid.
  - The types of the microemulsions formed are dependent on  
30 the ratio of aqueous phase to the nonionic surfactant(s) and oil. When the percentage of the salt solution

- 7 -

containing quaternary surfactant increases, the microemulsion changes from water-in-oil to oil-in-water type, and a bicontinuous microemulsion phase, or possibly a liquid crystal phase, will form in-between.

- 5   • The microemulsions can contain a high level of inorganic salts.
- The microemulsions contain a quaternary surfactant and a nonionic surfactant.
- The microemulsions contain cosmetically acceptable oils.
- 10   • A method for controlling or preventing underarm perspiration and malodor, which can be applied to the underarm area.
- The application of the microemulsions can be accomplished by using various product dispensers.

15

As used herein % means weight percent unless otherwise specified.

As used herein the term cationic surfactant means  
20 quaternary ammonium surfactant.

The starting materials set forth herein are either known or can be prepared according to known methods. The compositions of the invention can be made by known methods  
25 or by methods that are analogous to known methods.

As used herein, microemulsions mean stable clear microemulsions containing cosmetic oil; antiperspirant salts, water and surfactants. The microemulsions described  
30 herein are primarily composed of bicontinuous phase but the



- 8 -

compositions can include water-in-oil microemulsions. The compositions of the invention can also comprise a liquid crystal (that is, a microemulsion gel). More specifically, the compositions of the invention are selected from the

5 group consisting of a microemulsion, a liquid crystal (that is, microemulsion gel), or a mixture of a microemulsion and a liquid crystal. The compositions of the invention comprise an antiperspirant salt, a cosmetic oil, and a combination of at least one cationic quaternary surfactant and at least one

10 nonionic surfactant.

The compositions of the invention are novel antiperspirant compositions that can be used in different types of applicators such as roll-on, sponge, mousse, pad,

15 brush, wipe, gel and aerosol or non-aerosol spray applicators.

All of the microemulsion compositions described contain antiperspirant salts and are clear and stable over a larger

20 temperature range from room temperature to 45°C-50°C. The viscosity of some of the water-in-oil microemulsions are less than 10cst, therefore they are spray-able.

The invention relates to a composition in the form of a

25 microemulsion comprising an antiperspirant salt, cosmetic oils, and a combination of at least one cationic quaternary surfactant and at least one nonionic surfactant.

A description of the ingredients included in the

30 compositions of the invention now follows.

- 9 -

Antiperspirant Salts

Antiperspirant salts contained in these microemulsions include, but are not limited to, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum chlorohydrate propylene glycol complex, aluminum dichlorohydrate propylene glycol complex, aluminum sesquichlorohydrate propylene glycol complex, aluminum chlorohydrate polyethylene glycol complex, aluminum dichlorohydrate polyethylene glycol complex, aluminum sesquichlorohydrate polyethylene glycol complex, aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, aluminum zirconium trichlorohydrate glycine complex, aluminum zirconium tetrachlorohydrate glycine complex, aluminum zirconium pentachlorohydrate glycine complex, aluminum zirconium octachlorohydrate glycine complex, aluminum chloride or buffered aluminum sulfate.

20

Antiperspirant actives for use herein are often selected from astringent active salts, including in particular aluminum, zirconium and mixed aluminum/zirconium salts, including both inorganic salts, salts with organic anions and complexes. Preferred astringent salts include aluminum, zirconium and aluminum/zirconium halides and halohydrate salts, such as chlorohydrates.

Aluminum halohydrates are usually defined by the general formula  $Al_2(OH)_xQ_y$  or a hydrate thereof in which Q represents chlorine, bromine or iodine, x is variable from 2

- 10 -

to 5 and  $x+y=6$ . The level of hydration is variable for example wherein there are up to about 6 or higher water molecules.

5           Zirconium actives can usually be represented by the empirical general formula:  $ZrO(OH)_{2n-nz}B_z$  or a hydrate thereof in which  $z$  is a variable in the range of from 0.9 to 2.0 so that the value  $2n-nz$  is zero or positive,  $n$  is the valence of  $B$ , and  $B$  is selected from the group consisting of  
10 chloride, other halide, sulphamate, sulfate and mixtures thereof. Possible hydration to a variable extent is represented by  $wH_2O$ . It is preferable that  $B$  represents chloride and the variable  $z$  lies in the range from 1.5 to 1.87. In practice, such zirconium salts are usually not  
15 employed by themselves, but as a component of a combined aluminum and zirconium-based antiperspirant. The level of hydration is variable for example wherein there are up to about 6 or higher water molecules.

20           The above aluminum and zirconium salts may have coordinated and/or bound water in various quantities and/or may be present as polymeric species, mixtures or complexes. In particular, zirconium hydroxy salts often represent a range of salts having various amounts of the hydroxy group.  
25 Zirconium aluminum chlorohydrate may be particularly preferred.

          Antiperspirant complexes based on the above-mentioned astringent aluminum and/or zirconium salts can be employed.  
30 The complex often employs a compound with a carboxylate group, and advantageously this is an amino acid. Examples

- 11 -

of suitable amino acids include dl-tryptophan, dl- $\beta$ -phenylalanine, dl-valine, dl-methionine and  $\beta$ -alanine, and preferably glycine, which has the formula  $\text{CH}_2 (\text{NH}_2) \text{COOH}$ .

5           Complexes of a combination of aluminum halohydrates and zirconium chlorohydrates with or without with amino acids such as glycine can be employed in this invention. Certain of those Al/Zr-glycine complexes are commonly called ZAG in the literature. Aluminum-Zirconium actives or ZAG actives  
10           generally contain aluminum, zirconium and chloride with an Al/Zr ratio in a range from 2 to 10, especially 2 to 6, an Al/Cl ratio from 2.1 to 0.9. ZAG actives also contain a variable amount of glycine. In certain conditions, salts  
15           with an Al/Zr ratio greater than 2 (also known as low-zirconium actives) may be preferred. Actives of these preferred types are available from Westwood, from Summit and from Reheis.

          Other antiperspirant-salt actives that may be utilized  
20           include astringent titanium salts, for example those describe in GB 2299506A.

          The proportion of solid antiperspirant salt in a composition normally includes the weight of any water of  
25           hydration and any complexing agent that may also be present in the solid active. However, when the salt is in solution, its weight excludes any water present.

          The antiperspirant active will often provide from 1 to  
30           60% by weight of the aqueous phase, particularly from 10% to 60% of the aqueous phase. The final content of the salts in

- 12 -

the formulations can range from 0.1% to 40% but 5-35% is preferred.

#### Other Aqueous Phase Ingredients

5

In addition to aluminum salts, the microemulsions, discovered in this invention, could solubilize aqueous solutions of monovalent, divalent and trivalent salts. The salts include sodium chloride, sodium sulfate, calcium  
10 chloride, calcium sulfate, magnesium chloride, aluminum sodium lactate, and mixtures thereof.

Other ingredients which can be dissolved in the aqueous phase include buffers, glycols, sugars, cyclodextrins,  
15 preservatives, antimicrobials, fragrances, chelating agents, amino acids, antimicrobials, anticholinergics, water-soluble polymers etc.

#### Water Content

20

The antiperspirant salts or other aqueous phase ingredients can be dissolved into water first and then combined with the non-aqueous phase. Water content in the final formulations can range from 1% to 60%, 5% to 30% is  
25 preferred and 10% to 25% is the most preferred.

#### Oil Phase

The oil phase of the compositions of the invention can  
30 contain cosmetic oils such as esters, ethers, long chain alcohols or ethoxylated alcohols, hydrocarbons, fatty acids,

- 13 -

monoglycerides, diglycerides or triglycerides, fragrances, volatile or non-volatile silicone fluids. Cholesterol and some other lipids can be incorporated with the oil phase to act as emollients. The oil phase concentration can range  
5 from 0% to 95%, but 20% to 60% is preferred.

Silicone fluids that may be included in compositions of the invention include volatile and non-volatile silicone fluids such as cyclomethicones and dimethicones.

10

Non-volatile silicones such as phenyl tris(trimethylsiloxy)silane can be included in compositions of the invention.

15 Silicone elastomers such as DC 9040, or DC 9010 by Dow Corning or GE SFE 839 by General Electric, can be included in the compositions of the invention.

20 Esters selected from the group consisting of cetyl octanoate, C12 -15 alcohol benzoate, isostearyl benzoate, diisopropyl adipate, isopropyl palmitate, isopropyl myristate and mixtures thereof may be included in the compositions of the invention.

25 Hydrocarbon oils such as aliphatic hydrocarbons (Permethyl 102A <sup>TM</sup>, Permethyl 101<sup>TM</sup>); hydrogenated polybutenes; hydrogenated polydecenes (Silkflo<sup>TM</sup>); dioctylcyclohexane; mineral oil, cyclohexane and mixtures thereof may be included in the compositions of the  
30 invention.

- 14 -



SurfactantsQuaternary Ammonium Surfactants

5 Combinations of a cationic, quaternary ammonium  
surfactant(s) and a nonionic surfactant are employed in the  
compositions of the invention.

The quaternary surfactant in this invention is  
10 essential, without which the formulation will be either  
extremely sensitive to temperature or a microemulsion will  
not form. The preferred cationic surfactants employed in  
compositions of the invention are alkylamidopropyl  
alkyldimonium quaternaries.

15

The preferred cationic quaternary surfactants have the  
following structure:-



wherein n is one to six.

x is zero to three

25 y is zero to three

z is zero to three

- 15 -

with the proviso that  $x+y+z \leq 6$


A<sup>-</sup> is any physiologically acceptable counter ion which does not adversely affect the composition, and more specifically A<sup>-</sup> can be selected from the group consisting of chloride, bromide, ethosulfate, methyl sulfate, lactate, acetate, nitrate or sulfate.

where R is a ricinoleic derivative:

10         $\text{CH}_3 (\text{CH}_2)_5 \text{CH}(\text{OH}) \text{CH}_2\text{-CH=CH-} (\text{CH}_2)_7\text{-};$   
or mixtures thereof.

Obviously, variations on this structure, known to the art, can also be incorporated into embodiments of this invention. The variations on surfactant structure should exhibit solubility in the aqueous antiperspirant salt solution. If the above mentioned solubility is maintained then variations in the quaternary ammonium salts can include but are not limited to, increasing or decreasing the alkyl chain length, changing the position or removal of the hydroxyl group, changing the position or removing completely the double bond or combinations thereof.

The most preferred quaternary surfactant is ricinoleamidopropyl ethyldimonium ethosulfate a compound according to the formula above wherein  $n=3$ ,  $x=1$ ,  $y=0$ ,  $z=0$ , A<sup>-</sup> = ethosulfate and



30        The surfactant described just above is also known, under the following trade names, as Surfactol Q4 from



- 16 -

CasChem Inc., Lipoquat R from Lipo Chemicals or Mackernium DC-159 from McIntyre Chemical. Preferably the quaternary surfactant is supplied in a concentrated form (>90% active) with a low free amine content. This form is readily  
5 miscible with the aqueous antiperspirant-salt solution.

The quaternary surfactant(s) in the compositions of the invention range from 0.1% to 30%, where 2% to 15% is preferred.

10

#### Nonionic Surfactants

The nonionic surfactant or co-surfactants employed in the compositions of the invention can be polyethoxylated  
15 alcohol ethers or esters, polyglycerol mono or di-esters, glyceryl esters or branched guerbet ethoxylates or alcohols, or long chain carboxylic acids or combinations thereof. These compounds have a hydrophilic-lipophilic balance of between about 2 to about 15 and preferably less than about  
20 12. Non-limiting examples are polyglycerol-3 diisostearate; glycerol oleate; poly glycerol-2 monoisostearate; polyglycerol -2 diisostearate, glyceryl isostearate. The most preferred ones are polyglyceryl-3 diisostearate, glyceryl isostearate and glycerol oleate or combinations  
25 thereof.

The ratio of cationic surfactant to aqueous phase containing antiperspirant salt ranges from 30/70 to 4/96, the ratio from 10/90 to 5/95 is preferred. The ratio of  
30 aqueous phase including salts, water and cationic surfactant

- 17 -

to nonionic surfactant is 90/10 to 70/30, and the ratio from 90/10 to 80/20 is preferred.

### Formulation Examples

5

The following samples are stable for one month at room temperature. The particle size or domain length of these compositions are between about 150 to about 600 angstroms. All samples are clear. Some samples exhibit streaming  
10 birefringence. Some samples exhibit birefringence. The viscosity of these samples range from a thin liquid to a gel. These microemulsions are primarily composed of bicontinuous phase but the compositions include water-in-oil, and microemulsion gels (liquid crystals).

15

The following formulation examples are illustrative of the invention.

The following is a general formula for an  
20 antiperspirant microemulsion of the present invention.

25

30

- 18 -

General Formulation Example:

| Components                              |                     | Specific Examples of components                          | Range      | Preferred range               |
|---|---------------------|--|------------|-------------------------------|
| Oil Phase*                              |                     | Aliphatic Hydrocarbon 90-10%<br>Volatile Silicone 10-90% | 0-95%      | 20-60%                        |
| Aqueous Phase*                          | Water               | Deionized Water  | 1-60%      | 5-30%                         |
|   | Antiperspirant-Salt | ACH or AZG or other salts                                | 0.1-40%    | 5-35%                         |
| Non-ionic surfactant                    |                     | Polyglycerol-3 diisosterate                              | 0.2 to 30% | 4-15%<br>5-10% most preferred |
| Cationic Quaternary Ammonium Surfactant |                     | Ricinoleamidopropyl ethyl dimonium ethosulfate           | 0.1-30%    | 2-15%                         |

- 5      \*Cosmetic additives or other optional ingredients can be added to either phase as required.

## Generalized manufacturing procedure:

- 10    1. Weigh all the oil phase components into a suitable vessel and mix until homogenous. Heat may be used to expedite dispersion of components solid at room temperature.

- 19 -

2. The aqueous phase is prepared by mixing the quaternary ammonium surfactant with the antiperspirant salt solution.
3. Add the oil and water phases together and mix until a clear, homogenous dispersion is formed.
- 5 4. The microemulsion formulation is transferred into a suitable dispenser or applicator.

The following examples more fully illustrate embodiments of this invention, all percentages being by weight unless  
10 otherwise noted. The following specific examples, which are compositions of the invention, were made.

Compositions were prepared according to the following procedure:

15

1. Mix the cationic surfactant with the antiperspirant salt solution
  2. Mix the nonionic surfactant with the oil mixture, then add the two mixtures together and mix well.
  - 20 3. Heat may be applied to better dissolve solid nonionic surfactants, which are solid such as glyceryl oleate, in the oil phase prior to mixing the aqueous and non-aqueous phases
-

- 20 -

4.

|    | Prisorine 3700<br>%  | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>tetra<br>% | Water%     | DC245%      | HC*<br>%     |                  |
|----|----------------------|---------------------|---|------------|-------------|--------------|------------------|
| 1  | 10.03                | 5.98                | 13.55                                       | 20.31      | 15.04       | 35.09        |                  |
| 2  | 8.99                 | 4.66                | 10.57                                       | 15.85      | 17.98       | 41.95        |                  |
| 3  | 7.02                 | 3.45                | 7.82  | 11.74      | 20.99       | 48.98        |                  |
| 4  | 3.97                 | 1.73                | 3.93  | 5.91       | 25.34       | 59.12        |                  |
|    |                      |                     |   |            |             |              |                  |
| 5  | Prisorine 3700<br>%  | Cationic<br>**<br>% | ACH<br>%                                    | Water<br>% | DC245%      | HC<br>*<br>% |                  |
| 6  | 9.97                 | 6.78                | 19.2  | 19.2       | 13.45       | 31.40        |                  |
| 7  | 2.99                 | 1.02                | 2.89  | 2.90       | 27.06       | 63.14        |                  |
|    |                      |                     |   |            |             |              |                  |
|    | Glyceryl oleate<br>% | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>tetra<br>% | Water<br>% | DC 245<br>% | HC<br>*<br>% |                  |
| 8  | 14.24                | 11.71               | 22.09                                       | 33.13      | 5.65        | 13.18        |                  |
| 9  | 11.05                | 8.55                | 16.13                                       | 24.20      | 12.02       | 28.05        |                  |
| 10 | 10.02                | 7.89                | 14.88                                       | 22.33      | 13.46       | 31.42        |                  |
| 11 | 9.99                 | 6.98                | 13.17                                       | 19.75      | 15.03       | 35.08        | Birefri<br>ngent |
| 12 | 14.95                | 12.27               | 23.13                                       | 34.69      | 4.49        | 10.47        |                  |
|    |                      |                     |   |            |             |              |                  |
|    | Glyceryl oleate<br>% | Cationic<br>**<br>% | ACH<br>%                                    | Water<br>% | DC 245<br>% | HC<br>*<br>% |                  |
| 13 | 3.99                 | 12.91               | 36.57                                       | 36.57      | 2.99        | 6.97         |                  |
| 14 | 2.99                 | 1.83                | 5.17  | 5.18       | 25.45       | 59.38        | Birefri<br>ngent |
| 15 | 8.50                 | 7.70                | 21.82                                       | 21.82      | 12.05       | 28.11        |                  |
|    |                      |                     |   |            |             |              |                  |
|    | Prisorine 3700<br>%  | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>penta<br>% | Water<br>% | DC245%      | HC<br>*<br>% |                  |
| 16 | 16.64                | 8.67                | 23.2  | 34.8       | 5.01        | 11.68        | Birefri<br>ngent |
| 17 | 14.12                | 6.04                | 16.17                                       | 24.25      | 11.83       | 27.59        | Birefri<br>ngent |
| 18 | 7.46                 | 4.87                | 16.30                                       | 16.29      | 16.52       | 38.56        |                  |

- 21 -

|    | Glyceryl<br>isostearate<br>% | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>penta<br>% | Water<br>% | DC 245<br>% | HC<br>*<br>%                |                  |
|----|------------------------------|---------------------|---|------------|-------------|-----------------------------|------------------|
| 19 | 11.02                        | 11.09               | 25.15                                       | 37.72      | 4.51        | 10.51                       | Birefri<br>ngent |
| 20 | 10.02                        | 8.99                | 20.37                                       | 30.55      | 9.02        | 21.05                       | Birefri<br>ngent |
| 21 | 9.03                         | 7.64                | 17.32                                       | 25.99      | 12.00       | 28.02                       | Birefri<br>ngent |
| 22 | 7.97                         | 6.32                | 14.32                                       | 21.47      | 14.98       | 34.94                       |                  |
| 23 | 6.02                         | 3.60                | 8.15  | 12.22      | 21.00       | 49.01                       |                  |
|    | Glyceryl<br>isostearate<br>% | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>penta<br>% | Water<br>% | DC 245<br>% | HC<br>*<br>%                |                  |
| 24 | 6.02                         | 4.434               | 7.82  | 11.72      | 21.00       | 49.01                       |                  |
| 25 | 8.52                         | 13.64               | 24.03                                       | 36.05      | 5.33        | 12.43                       |                  |
| 26 | 9.00                         | 5.71                | 8.72  | 16.46      | 18.03       | 42.08                       |                  |
| 26 | 4.68                         | 0.14                | 0.25  | 0.38       | 28.36       | 66.19                       |                  |
| 27 | 9.74                         | 0.46                | 0.81  | 1.21       | 26.33       | 61.45                       |                  |
|    | Glyceryl<br>isostearate<br>% | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>penta<br>% | Water<br>% | DC 245<br>% | HC<br>*<br>%                |                  |
| 28 | 11.47                        | 11.80               | 26.76                                       | 40.13      | 2.95        | 6.89                        | Birefri<br>ngent |
| 29 | 11.11                        | 11.07               | 25.10                                       | 37.65      | 4.52        | 10.55                       |                  |
| 30 | 10.03                        | 6.74                | 15.29                                       | 22.93      | 13.50       | 31.51                       |                  |
| 31 | 9.54                         | 6.06                | 13.73                                       | 20.60      | 15.02       | 35.05                       |                  |
| 32 | 11.38                        | 11.91               | 27.00                                       | 40.51      | 2.76        | 6.44                        |                  |
|    | Glyceryl<br>isostearate<br>% | Cationic<br>**<br>% | Alumin<br>um<br>Zircon<br>ium<br>penta<br>% | Water<br>% | DC 245<br>% | Silkofl<br>o<br>366-NF<br>% |                  |
| 33 | 7.45                         | 16.94               | 30.34                                       | 44.66      | 0.43        | 0.18                        | Birefri<br>ngent |
| 34 | 12.36                        | 11.88               | 22.40                                       | 33.59      | 13.85       | 5.92                        | Birefri<br>ngent |
| 35 | 12.06                        | 11.92               | 22.47                                       | 33.71      | 13.89       | 5.95                        |                  |
| 36 | 12.05                        | 9.26                | 17.46                                       | 26.19      | 24.53       | 10.51                       |                  |
| 37 | 10.93                        | 7.78                | 14.67                                       | 22.01      | 31.23       | 13.38                       |                  |

- 22 -

|    | Prisorine 3700<br>%                                | Cationic<br>**<br>% | Aluminum<br>Zirconium<br>penta<br>% | Water<br>% | DC 245<br>% | Silkflo<br>366-NF<br>% |              |
|----|--|---------------------|-------------------------------------|------------|-------------|------------------------|--------------|
| 38 | 10.67  | 11.19               | 25.36                               | 38.05      | 10.31       | 4.42                   | Birefringent |
| 39 | 14.01  | 9.89                | 22.41                               | 33.61      | 14.06       | 6.02                   |              |
| 40 | 4.93   | 2.22                | 5.03                                | 7.55       | 56.20       | 24.07                  |              |
| 41 | 13.98  | 6.90                | 15.64                               | 23.45      | 28.02       | 12.01                  |              |
| 42 | 11.51  | 5.77                | 13.08                               | 19.62      | 35.02       | 15.00                  |              |
| 43 | 9.51   | 4.58                | 10.37                               | 15.56      | 41.98       | 18.00                  |              |
| 44 | 7.98   | 3.32                | 7.52                                | 11.28      | 48.93       | 20.97                  |              |
|    | Prisorine 3700<br>%                                | Cationic<br>**<br>% | Aluminum<br>Zirconium<br>penta<br>% | Water<br>% | DC 245<br>% | Silkflo<br>366-NF<br>% |              |
| 45 | 11.05  | 13.48               | 25.42                               | 38.08      | 8.34        | 3.63                   |              |
| 46 | 12.03  | 11.91               | 22.46                               | 33.70      | 13.92       | 5.98                   |              |
| 47 | 11.96  | 9.80                | 18.49                               | 27.73      | 22.41       | 9.61                   | Birefringent |
| 48 | 15.96  | 11.22               | 21.16                               | 31.73      | 13.95       | 5.98                   | Birefringent |
| 49 | 14.03  | 9.78                | 18.44                               | 27.66      | 21.06       | 9.03                   |              |
|    | Isofol 12<br>alcohol<br>ethoxylate/<br>cholesterol | Cationic<br>**<br>% | ACH %                               | Water<br>% | DC245%      | HC<br>*<br>%           |              |
| 50 | 20.15/0  | 8.21                | 23.26                               | 23.26      | 7.52        | 17.60                  | Birefringent |
| 51 | 12.71/2.44   | 6.72                | 18.85                               | 18.85      | 12.12       | 28.31                  |              |

\* HC means hydrocarbon: Permethyl 102A, listed in the above table

\*\* Cationic means the cationic surfactant:

5 Ricinoleamidopropyl ethyldimonium ethosulphate

Further examples include:

Example 52

- 23 -

| Ingredient (INCI)                        | Trade Names           | Source       | Percent |
|--|-----------------------|--------------|---------|
| Ricinoleamidopropyl Dimonium Ethosulfate | Surfactol Q4          | CasChem, Inc | 7.50%   |
| Polyglycerol-3 Diisostearate             | Prisorine PG3 DI 3700 | Uniqema      | 10%     |
| Aliphatic Hydrocarbon                    | Permethyl 102A        | Presperse    | 28%     |
| Cyclopentasiloxane                       | DC245                 | Dow Corning  | 12%     |
| Aluminum Chlorohydrate 50%               | Westchlor 200         | Westwood     | 42.50%  |
|  |                       | Total:       | 100%    |

## Example 53

| Ingredient (INCI)                         | Trade Names                           | Source         | Percent |
|---|---------------------------------------|----------------|---------|
| Ricinoleamidopropyl Dimonium Ethosulfate  | Surfactol Q4                          | CasChem, Inc   | 7.50%   |
| Glyceryl Isostearate                      | Peceol Isostearique                   | Gattefosse     | 10%     |
| Hydrogenated Polydecene                   | Silkflo 366                           | Lipo Chemicals | 12%     |
| Cyclopentasiloxane                        | DC245                                 | Dow Corning    | 28%     |
| Aluminum Zirconium Pentachlorohydrate 40% | Low Zirconium Penta Solution R280-130 | Reheis         | 42.50%  |
|   |                                       | Total:         | 100%    |



- 24 -

## Example 54

| Ingredient (INCI)                             | Trade Names                           | Source         | Percent |
|---|---------------------------------------|----------------|---------|
| Ricinoleamidopropyl Dimonium Ethosulfate      | Surfactol Q4                          | CasChem, Inc   | 2.77%   |
| Aluminum Zirconium Pentachlorohydrate 40%     | Low Zirconium Penta Solution R280-130 | Reheis         | 47.63%  |
| Glyceryl Isostearate                          | Peceol Isostearique                   | Gattefoss e    | 3.06%   |
| Hydrogenated Polydecene                       | Silkflo 366                           | Lipo Chemicals | 11.70%  |
| Cyclopentasiloxane                            | DC245                                 | Dow Corning    | 27.04%  |
| Ethoxylated Guerbet Alcohol C14 / 4 EO HLB ~9 | Novel II Isofol 14T+4EO               | Condea Vista   | 7.80%   |
|   |                                       | Total:         | 100%    |

## 5 Examples 55 and 56

| Ingredient (INCI)  | Trade Names                 | Supplier        | 55       | 56       |
|--|-----------------------------|-----------------|----------|----------|
|  |                             |                 | Per-cent | Per-cent |
| Ricinoleamidopropyl ethyl dimonium ethosulfate               | Surfactol Q4                | Caschem         | 2.32     | 2.83     |
| Aluminum zirconium penta cholorohydrate                      | Rezal 67                    | Reheis          | 15.94    | 18.13    |
| Water  | Deionized Water             | Stock           | 23.91    | 27.19    |
| Urea   | Urea                        | Janssen Chimica | -        | 3.34     |
| Cyclopentasiloxane   | DC 245                      | Dow Corning     | 29.08    | 22.08    |
| Polydecene hydrogenated                                      | Silkflo366NF                | Lipo Chemicals  | 11.62    | 9.46     |
| Glyceryl isostearate   | Peceol isostearique         | Gattefosse      | 5.26     | -        |
| Polyglyceryl-3 diisostearate                                 | Prisorine 3700              | Unichema        | 0.87     | 3.49     |
| Ethoxylated Guerbet alcohol C <sub>18</sub> EO <sub>10</sub> | Novel II I18T-10 ethoxylate | Condea Vista    | 3.36     | 6.19     |
| 2-hexyldecanol (Guerbet C16 Alcohol)                         | Isoflo 16                   | Condea Vista    | 7.64     | 7.29     |
|  |                             | Total           | 100      | 100      |

- 25 -

Raw materials used in preparation of the example compositions of the invention are as follows:

| Trade Name          | Chemical Name                  | Vender                   |
|---------------------|--------------------------------|--------------------------|
| DC 245              | Cyclomethicone D5              | Dow Corning              |
| DC 344              | Cyclomethicone D4              | Dow Corning              |
| Silkflo 364 or 366  | Hydrogenated Polydecene        | Lipo Chemical            |
| Permethyl 102 A     | Aliphatic hydrocarbon          | Permethyl Specialties    |
| Permethyl 101       | Aliphatic hydrocarbon          | Permethyl Specialties    |
| Trivent OC-16       | Cetyl octanoate                | Trivent Chemical Company |
| Cetiol S            | Diethyl cyclohexane            | Henkel Corporation       |
| Peceol Isostearique | Glyceryl isostearate           | Gattefosse               |
| Monomuls 90-018     | Glycerol oleate                | Henkel Corporation       |
| Fancol Polyiso 275  | Hydrogenated polyisobutene     | The Fanning Corp.        |
| Finsolve TN         | C12-C15 alcohol benzoate       | Finetex                  |
| Finsolve SB         | Isostearyl benzoate            | Finetex                  |
| Prisorine 3700      | Polyglycerol -3 Diisostearate  | Unichema North America   |
| Prisorine 3792      | Polyglycerol-2 diisostearate   | Unichema North America   |
| Prisorine 3791      | Polyglycerol-2 monoisostearate | Unichema North America   |
| Glucate DO          | Methyl glucoside dioleate      | Amercol                  |
| Glucate SS          | Methyl glucoside sesquisteate  | Amercol                  |

- 26 -

|                 |                                    |                        |
|-----------------|------------------------------------|------------------------|
| Estol 3609      | Glycerol tri-2-ethylhexanoate      | Unichema North America |
| Dow Corning 556 | Phenyl tris(trimethylsiloxy)silane | Dow Corning            |

| Trade Name                                   | Chemical Name  | Vender               |
|--|--|----------------------|
| Ceraphyl 230                                 | Diisopropyl Adipate                                  | ISP Van Dyk Inc      |
| Mineral oil                                  | Hydrocarbon  | Witco                |
| Novel II 12-5 Ethoxylate                     | Ethoxylated alcohol or Branched Guerbert ethoxylate  | Condea Vista Company |
| Cholesterol                                  | Cholesterol  | Rita Corporation     |
| Surfactol Q4                                 | Ricinoleamidopropyl dimonium sulfate                 | CasChem              |
| Westchlor 200 50% w/w                        | Aluminum chlorohydrate (ACH)                         | West Wood            |
| Low zirconium penta solution R280-130 40%w/w | Low zirconium: Aluminum Zirconium Pentachlorohydrate | Reheis               |
| Rezal 67 Solution 40%w/w                     | Aluminum Zirconium Pentachlorohydrate (penta)        | Reheis               |
| Westchlor Zr 44 50% w/w                      | Aluminum Zirconium tetrachlorohydrate (tetra)        | West Wood            |
| Westchlor Zr 41 45%w/w                       | Aluminum Zirconium tetrachlorohydrate-glycine        | West Wood            |

5

The foregoing description and examples illustrate selected embodiments of the present invention. In light thereof, various modifications would be suggested to one skilled in the art, all of which are within the spirit and scope of this invention.

10

- 27 -

Claims:

1. A composition which is selected from the group consisting of a microemulsion, a liquid crystal, or a mixture of a microemulsion and a liquid crystal which comprises an antiperspirant salt, a cosmetic oil, and a combination of at least one cationic quaternary surfactant and at least one nonionic surfactant.
2. A composition in accordance with claim 1 characterised in that said antiperspirant salt is selected from the group consisting of aluminum, zirconium and mixed aluminum/zirconium salts.
3. A composition in accordance with claim 1 or 2 characterised in that said antiperspirant salt is a zirconium salt complexed with aluminum salts having coordinated or bound water.
4. A composition in accordance with any preceding claim characterised in that said antiperspirant salt is present in the aqueous phase at from about 1 to about 60%.
5. A composition in accordance with claim 4 characterised in that said antiperspirant salt is present in the aqueous phase at from 10% to about 60%.
6. A composition in accordance with any preceding claim characterised in that said aqueous phase further comprises a buffer, a glycol, a sugar, a cyclodextrin,

- 28 -

a preservative, an antimicrobial, a chelating agent, a water-soluble polymer, an anticholinergic, a monovalent salt, a divalent salt, a trivalent salt, fragrances or mixtures thereof.

5

7. A composition in accordance with any preceding claim in which said aqueous phase is present at about 1% to about 60%, more preferably at 5% to 30%, and most preferably at 10 to 25%.

10

8. A composition in accordance with any preceding claim characterised in that said cosmetic oil comprises esters, ethers, long chain alcohols or ethoxylated alcohols, hydrocarbons, fatty acids, monoglycerides, diglycerides triglycerides, fragrances and volatile or non-volatile silicone fluids, and cholesterol.

15

9. A composition in accordance with claim 8 characterised in that said oil phase comprises silicone fluids which in turn comprise a volatile or non-volatile silicone such as cyclomethicone or dimethicone.

20

10. A composition in accordance with claim 8 or 9 characterised in that said non-volatile silicone is phenyl tris(trimethylsiloxy)silane.

25

11. A composition in accordance with claim 8 characterised in that said esters are selected from the group consisting of cetyl octanoate, C12 -15 alcohol benzoate, isostearyl benzoate, diisopropyl adipate and mixtures thereof.

30

- 29 -

12. A composition in accordance with claim 8 wherein said hydrocarbon fluids are selected from the group such as aliphatic hydrocarbons; hydrogenated polydecenes; hydrogenated polybutenes; dioctylcyclohexane; mineral oil, cyclohexane and mixtures thereof.
13. A composition in accordance with any preceding claim characterised in that the cationic quaternary ammonium surfactant has the following structure:
- $$\begin{array}{c} /-(CH_2)_x-CH_3 \\ R-CO-NH-(CH_2)_n-N^+-(CH_2)_z-CH_3 \quad A^- \\ \backslash-(CH_2)_z-CH_3 \end{array}$$
- wherein n is one to six.
- x is zero to three  
y is zero to three  
z is zero to three
- with the proviso that  $x+y+z \leq 6$
- A<sup>-</sup> is any physiologically acceptable counter ion which does not adversely affect the composition, and more specifically A<sup>-</sup> can be selected from the group consisting of chloride, bromide, ethosulfate, methyl sulfate, lactate, acetate, nitrate or sulfate.
- where R is a ricinoleic derivative:
- $$CH_3 (CH_2)_5 CH(OH) CH_2-CH=CH- (CH_2)_7-$$
- Or mixtures thereof.
14. A composition in accordance with claim 13 wherein n=3, x=1, y=0, z=0, A<sup>-</sup> = ethosulfate and R = CH<sub>3</sub>-(CH<sub>2</sub>)<sub>5</sub>-CH(OH)-CH<sub>2</sub>-CH=CH-(CH<sub>2</sub>)<sub>7</sub>-.

- 30 -

15. A composition in accordance with any preceding claim characterised in that said cationic quaternary ammonium surfactant is present at 0.1% to 30%, more preferably at 1% to 30%, most preferably at 2% to 15%.

5

16. A method for controlling or preventing underarm perspiration and malodor which comprises applying, to an underarm, an effective amount of a composition of claim 1.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09144

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/00 A61K7/32 A61K7/34 A61K7/38

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | US 5 487 887 A (BENFATTO)<br>30 January 1996 (1996-01-30)<br>cited in the application<br>the whole document<br>---                                   | 1-10,<br>13-16        |
| Y          | EP 0 278 660 A (STIEFEL LABORATORIES<br>(IRELAND) LIMITED)<br>17 August 1988 (1988-08-17)<br>page 2, line 36 -page 3, line 47<br>examples 1-8<br>--- | 1-9, 15,<br>16        |
| Y          | WO 97 06777 A (THE MENNEN COMPANY)<br>27 February 1997 (1997-02-27)<br>examples 10-13<br>---<br>-/--   | 10                    |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

1 March 2001

Date of mailing of the international search report

08/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alvarez Alvarez, C



# INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 00/09144

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | <p>SWAFFORD ET AL.: "Characterization of swollen micelles containing linoleic acid in a microemulsion system"</p> <p>J. SOC. COSMET. CHEM.,<br/>vol. 42, no. 4, 1991, pages 235-247,<br/>XP000984183<br/>figure 1</p> <p>-----</p> | 13-15                 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09144

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US 5487887 A                              | 30-01-1996          | US 5575990 A               | 19-11-1996          |
| EP 278660 A                               | 17-08-1988          | IE 60024 B                 | 18-05-1994          |
|   |                     | AT 81279 T                 | 15-10-1992          |
|   |                     | BE 1000281 A               | 04-10-1988          |
|   |                     | DE 3875128 A               | 12-11-1992          |
|   |                     | DE 3875128 T               | 29-04-1993          |
| WO 9706777 A                              | 27-02-1997          | AU 711443 B                | 14-10-1999          |
|   |                     | AU 6718296 A               | 12-03-1997          |
|   |                     | BR 9610156 A               | 05-10-1999          |
|   |                     | CA 2229742 A               | 27-02-1997          |
|   |                     | EP 0845977 A               | 10-06-1998          |
|   |                     | US 6007799 A               | 28-12-1999          |